Surlorian

DRUG2 trials

Sponsors

Rycarma Therapeutics Inc., RyCarma Therapeutics, Inc.

Conditions

Autosomal Dominant RYR1-Related Myopathy

Phase 2

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of surlorian (ARM210, S48168) in Adults with Autosomal Dominant RYR1-Related Myopathy

Not yet recruitingCTIS2025-522343-18-00

Rycarma Therapeutics Inc.Autosomal Dominant RYR1-Related Myopathy

Target: 27Updated: 2026-04-02

A Trial to Compare Treatment With Surlorian (ARM210, S48168) to Placebo in Effects on Muscle Strength and Safety in Adults With Autosomal Dominant RYR1-related Myopathy

RecruitingNCT07560020

RyCarma Therapeutics, Inc.Autosomal Dominant RYR1-Related Myopathy

Start: 2026-07-01End: 2028-08-27Target: 28Updated: 2026-07-15